logo
ProofPilot Teams Up with Inspire to Boost Patient Participation in Clinical Trials

ProofPilot Teams Up with Inspire to Boost Patient Participation in Clinical Trials

ProofPilot, the leading end-to-end Clinical Experience Platform (CXP), has partnered with Inspire, the world's leading online health community and patient engagement platform, to dramatically expand patient recruitment for clinical trials.
ProofPilot's platform is purpose-built to optimize recruitment and engagement of patients. By joining ProofPilot's Patient Recruitment Network, Inspire will help activate patients and caregivers from its diverse, global community, empowering them to find the right trials.
The partnership will help to bolster Inspire's impact by:
Expanding opportunities to connect patients in their community with life-advancing clinical trials
Providing a world class, end to end digital experience to optimize participation
'The Inspire community is filled with individuals eager to participate in the advancement and transformation of clinical research,' said Brett Kleger, CEO of Inspire. 'By partnering with a tech company like ProofPilot, we can seamlessly connect patients to meaningful clinical trial opportunities, allowing us to focus on what we do best – holistic, year-round engagement of our community.'
'At ProofPilot, we're committed to transforming the clinical trial experience for both sponsors and patients,' said Chris Venezia, CEO of ProofPilot. 'Our partnership with Inspire allows us to leverage their extensive patient community to accelerate recruitment and connect patients with life-changing research opportunities. We're excited to work with Inspire to break down barriers to study participation.'
About Inspire
Founded in 2005, Inspire connects life sciences organizations with the voices that matter most—patients and caregivers. With a community spanning over 10 million unique annual visitors and more than 3,000 disease states, Inspire leverages its engaged patient communities to deliver critical insights that drive advancements in both research and commercial strategy. Inspire's capabilities include accelerating clinical trial recruitment, uncovering real-world evidence, delivering actionable market research, and providing targeted advertising solutions that reach highly engaged health-focused audiences. By bridging the gap between patients and life sciences, Inspire enables smarter decision-making, more impactful treatments, and a deeper understanding of the communities it serves. Learn more at https://inspireresearch.com.
https://www.proofpilot.com and connect with us on LinkedIn.
Media Contact

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Inspire Medical Systems, Inc. to Participate in the Wells Fargo 2025 MedTech Innovation Spotlight
Inspire Medical Systems, Inc. to Participate in the Wells Fargo 2025 MedTech Innovation Spotlight

Yahoo

time3 days ago

  • Yahoo

Inspire Medical Systems, Inc. to Participate in the Wells Fargo 2025 MedTech Innovation Spotlight

MINNEAPOLIS, May 30, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will participate in the Wells Fargo 2025 MedTech Innovation Spotlight on Friday, June 13, 2025. Inspire is scheduled to present at 12:00 p.m. Eastern Time. The presentation will be accessible via a live webcast here. A webcast replay of the presentation will be available for two weeks following the presentation in the Event Archive section of Inspire's Investor website at About Inspire Medical SystemsInspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire's proprietary Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. For additional information about Inspire, please visit Investor and Media ContactEzgi YagciVice President, Investor Relationsezgiyagci@ in to access your portfolio

New sleep apnea therapy offered at CarolinaEast Health System
New sleep apnea therapy offered at CarolinaEast Health System

Yahoo

time5 days ago

  • Yahoo

New sleep apnea therapy offered at CarolinaEast Health System

NEW BERN, N.C. (WNCT) — A medical team with the CarolinaEast Health System are offering a new solution for those who struggle with a CPAP machine. Medical personnel with the Ear, Nose and Throat section of CarolinaEast are now making Inspire therapy available to the public. They have just completed their 50th Inspire implant. Inspire therapy helps those who have obstructive sleep apnea and struggle to use a CPAP. It offers a long-term and mask-free solution by syncing with the patient's natural breathing pattern and keeps their airway open. 'We are excited to stay on the cutting edge of technology for our patients in coastal NC,' stated Dr. McNabb, Otolaryngologist. 'The new Inspire therapy is one more tool to help those who suffer from sleep apnea get the rest they need.' The procedure involves two incisions, one in the chest and one under the chin where the nerve that controls the airway muscles is located. The Inspire implant and breathing sensors are placed in the chest incision. A handheld remote is given to the patient for them to turn the implant on when they're ready to sleep. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

FDA Approves Liquidia Corporation (LQDA)'s YUTREPIA Amid Patent Dispute
FDA Approves Liquidia Corporation (LQDA)'s YUTREPIA Amid Patent Dispute

Yahoo

time24-05-2025

  • Yahoo

FDA Approves Liquidia Corporation (LQDA)'s YUTREPIA Amid Patent Dispute

Liquidia Corporation (NASDAQ:LQDA) announced today that the U.S. Food and Drug Administration (FDA) has approved YUTREPIA (treprostinil) inhalation powder for adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). A healthcare professional working on a computer terminal with a patient in the background. YUTREPIA, enabled by Liquidia Corporation (NASDAQ:LQDA)'s proprietary PRINT technology, is the first and only prostacyclin dry-powder formulation designed for deep-lung delivery using a low-effort, portable inhalation device. The approval is based on results from the Phase 3 INSPIRE trial, which showed YUTREPIA to be safe and well-tolerated, offering a new treatment option for over 105,000 U.S. patients suffering from PAH and PH-ILD. Liquidia Corporation (NASDAQ:LQDA)'s commercial team is preparing to launch YUTREPIA, aiming to improve exercise ability and quality of life for patients. However, United Therapeutics Corporation has filed a patent infringement lawsuit and is seeking a court order to block YUTREPIA's commercial launch, with a decision on the injunction still pending. While we acknowledge the potential of LQDA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LQDA and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store